Candidiasis News and Research

RSS
Candiadiasis, or Thrush, is a fungal infection caused by a group of yeast. There is a score of Candida species, the commonest of which is Candida albicans. They normally inhabit the surfaces and mucus linings of the human body. This includes mouth, vaginal cavity gastrointestinal tract etc.
PolyMedix announces publication of defensin-mimetic compounds in Molecular Oral Microbiology

PolyMedix announces publication of defensin-mimetic compounds in Molecular Oral Microbiology

NIH awards Polymedix $986,000 to develop defensin mimetic antimicrobial compounds for oral candidiasis

NIH awards Polymedix $986,000 to develop defensin mimetic antimicrobial compounds for oral candidiasis

Candida Force program of detoxification and dietary recommendations effective for weight reduction

Candida Force program of detoxification and dietary recommendations effective for weight reduction

BioAlliance Pharma launches Oravig drug in the U.S. market

BioAlliance Pharma launches Oravig drug in the U.S. market

Montana State University offers new biomedical technologies for prevention, treatment of viral infections

Montana State University offers new biomedical technologies for prevention, treatment of viral infections

Par Pharmaceutical second-quarter total net revenues decrease 37% to $255.5 million

Par Pharmaceutical second-quarter total net revenues decrease 37% to $255.5 million

Perrigo files ANDA for butoconazole nitrate vaginal cream

Perrigo files ANDA for butoconazole nitrate vaginal cream

Study compares denture stomatitis genes with whole transcriptome for salivary biomarker analysis

Study compares denture stomatitis genes with whole transcriptome for salivary biomarker analysis

Starpharma gets FDA nod to start phase 2 bacterial vaginosis study for VivaGel

Starpharma gets FDA nod to start phase 2 bacterial vaginosis study for VivaGel

BioAlliance Pharma presents abstracts on Loramyc, clonidine Lauriad at MASCC/ISOO 2010 symposium

BioAlliance Pharma presents abstracts on Loramyc, clonidine Lauriad at MASCC/ISOO 2010 symposium

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010

Strativa Pharmaceuticals: Oravig buccal tablets receive FDA approval for OPC

Strativa Pharmaceuticals: Oravig buccal tablets receive FDA approval for OPC

FDA approves BioAlliance Pharma's Oravig for OPC

FDA approves BioAlliance Pharma's Oravig for OPC

Pevion Biotech commences Phase 1 clinical trial of PEV7 vaccine

Pevion Biotech commences Phase 1 clinical trial of PEV7 vaccine

Researchers to receive more than $4.5 million in grants to study Sudden Infant Death Syndrome

Researchers to receive more than $4.5 million in grants to study Sudden Infant Death Syndrome

BioAlliance Pharma wins first prize in Deloitte's Technology Fast 50 2009

BioAlliance Pharma wins first prize in Deloitte's Technology Fast 50 2009

Phase III study results on miconazole Lauriad presented by BioAlliance Pharma

Phase III study results on miconazole Lauriad presented by BioAlliance Pharma

Genetic mutations may put individuals at increased risk for fungal infections

Genetic mutations may put individuals at increased risk for fungal infections

Scientists identify genetic mutations that may put individuals at increased risk of fungal infections

Scientists identify genetic mutations that may put individuals at increased risk of fungal infections

US Army grants BioDelivery Sciences $1.3M for investigating Bioral Amphotericin B

US Army grants BioDelivery Sciences $1.3M for investigating Bioral Amphotericin B